IP Library Granted Patent US 7,605,235
Granted Patent B2
US 7,605,235 · App. 11/010,797 · Granted Oct 20, 2009

Anti-tissue factor antibodies and compositions

Assignee: Centocor, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,605,235
App. No.
11/010,797
Granted
Oct 20, 2009
Kind
B2
Abstract

Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.

Claims (9)

1. An isolated antibody which binds tissue factor having the heavy chain amino acid sequence consisting of SEQ ID NO:2, and the light chain amino acid sequence consisting of SEQ ID NO:4.

2. The isolated antibody of claim 1 , wherein the antibody binds to human tissue factor integrin subunit with a K D Of 10 −9 M or less.

3. A composition comprising at least one isolated mammalian anti-tissue factor antibody according to claim 1 , and at least ine pharmaceutically acceptable carrier or diluent.

4. A composition according to claim 3 wherein the antibody is combined with an anti-neoplastic agent selected from a radiopharmaceutical, an estrogen receptor modulator, a retinoid, a topoisomererase inhibitor, a cytotoxin, an alkylating agent, a nitrogen mustard, a nitrosourea, an antimetabolite, a mitotic inhibitor, and a radiosensitizer.

5. A composition according to claim 4 wherein the anti-neoplastic agent is dacarbazine.

6. An immunoconjugate comprising the antibody according to claim 1 linked to a therapeutic agent.

7. The immunoconjugate of claim 6 wherein the therapeutic agent is a cytotoxin.

8. The immunoconjugate of claim 6 wherein the therapeutic agent is a radioisotope.

9. A pharmaceutical composition comprising the immunoconjugate of any one of claims 6 - 8 and a pharmaceutically acceptable carrier.

Assignments (3)
MERGER Recorded Nov 12, 2012
From: CENTOCOR, INC.; ORTHO BIOTECH INC.
To: CENTOCOR ORTHO BIOTECH, INC.
Reel/Frame 029277/0719 →
CHANGE OF NAME Recorded Nov 12, 2012
From: CENTOCOR ORTHO BIOTECH, INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 029277/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2005
From: ANDERSON, G. MARK; SCALLON, BERNARD; NASO, MICHAEL; CAI, ANN; NGO, CAM
To: CENTOCOR, INC.
Reel/Frame 016682/0050 →
Continuity (3)
Continuation In Part 1085566400 · May 27, 2004
Provisional Application 6047517400 · May 30, 2003
Related Publication 20050220793A1 · Oct 6, 2005